Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06010342

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Led by Teligene US · Updated on 2026-04-28

60

Participants Needed

19

Research Sites

298 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions

CONDITIONS

Official Title

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years old and above, male or female
  • Confirmed diagnosis of locally advanced or metastatic solid tumor with NTRK1/2/3 gene fusion producing a functional TRK kinase domain, without another onco-driver
  • Disease progression after prior treatment, or unsuitable for standard care as judged by investigator; prior TRK inhibitor treatment allowed only if less than 28 days due to toxicity
  • At least one measurable lesion
  • ECOG performance status of 0, 1, or 2
  • Minimum life expectancy greater than 3 months
  • Adequate bone marrow, liver, kidney, and coagulation functions
  • Other inclusion criteria as per study protocol
Not Eligible

You will not qualify if you...

  • Systemic anti-tumor therapy (chemotherapy, radiation including curative or spinal >30%) within 3 weeks before enrollment; immunotherapy within 4 weeks; palliative radiotherapy or traditional Chinese medicines for tumor within 2 weeks
  • Participation in another interventional trial within 2 weeks or within 5 half-lives of last investigational product dose
  • Unresolved toxicities from prior therapy greater than Grade 1, except those posing no safety risk
  • Active central nervous system metastases
  • Other primary malignant tumors within 3 years, except cured skin basal cell carcinoma or in situ cervix cancer of low risk
  • Active uncontrolled infection
  • Other exclusion criteria as per study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 19 locations

1

Adventist Health Glendale

Glendale, California, United States, 91206

Actively Recruiting

2

Texas Oncology

Dallas, Texas, United States, 75251

Actively Recruiting

3

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

4

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Actively Recruiting

5

Peking University School and Hospital of Stomatology

Beijing, Beijing Municipality, China

Actively Recruiting

6

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

Actively Recruiting

7

Fujian Cancer Hospital

Fuzhou, Fujian, China

Actively Recruiting

8

Affiliated Cancer Hospital and Institute of Guangzhou Medical University

Guangzhou, Guangdong, China

Actively Recruiting

9

Harbin medical university cancer hospital

Harbin, Heilongjiang, China

Actively Recruiting

10

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Actively Recruiting

11

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Actively Recruiting

12

Hunan Cancer Hospital

Changsha, Hunan, China

Actively Recruiting

13

Jiangxi Cancer Hospital

Nanchang, Jiangxi, China

Actively Recruiting

14

Shanxi Cancer Hospital

Xi'an, Shaanxi, China

Actively Recruiting

15

Jinan Central Hospital

Jinan, Shandong, China

Actively Recruiting

16

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Actively Recruiting

17

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Actively Recruiting

18

Affiliated Cancer Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

Actively Recruiting

19

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Actively Recruiting

Loading map...

Research Team

X

Xiaoyang Xia

CONTACT

D

Dawei Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | DecenTrialz